Table 3: Approved vaccine by platform, number of trials, and number of countries.
|
Company/Organization |
Name of Vaccine |
Platform |
# Of Trials |
Approval in # of countries |
|
Pfizer/BioNTech |
Comirnaty |
RNA |
87 |
146 |
|
Oxford/AstraZeneca |
Vaxzevria |
NRVV |
69 |
141 |
|
Moderna |
Spikevax |
RNA |
68 |
87 |
|
Janssen (Johnson & Johnson) |
Ad26.CoV2.S |
NRVV |
24 |
111 |
|
Novavax |
Nuvaxovid |
Protein Subunit |
39 |
20 |
|
Serum Institu of India (Oxford/Astra Zeneca Formulation) |
Covishield |
NRVV |
4 |
49 |
|
Sinopharm (Beijing) |
Covilo |
Inactivated |
37 |
91 |
|
Sinovac |
Cornoavac |
Inactivated |
40 |
56 |
|
Valneva |
VLA2001 |
Inactivated |
6 |
33 |
|
Gamaleya |
Sputnik Light |
NRVV |
26 |
7 |
|
Gamaleya |
Sputnik V |
NRVV |
74 |
25 |
|
Bharat Biotech |
Covaxin |
Inactivated |
14 |
14 |
|
Medicago |
Covafin |
VLP |
6 |
1 |
NRVV: Non-Replicating Viral Vector; VLP: Virus-like Particle. For further information one can refer to the vaccine tracker [77].